<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03350542</url>
  </required_header>
  <id_info>
    <org_study_id>S2356</org_study_id>
    <nct_id>NCT03350542</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)</brief_title>
  <acronym>EVOLVE48</acronym>
  <official_title>EVOLVE 48: A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of the SYNERGY 48 mm Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this&#xD;
      study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm&#xD;
      Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) &gt; 34 mm&#xD;
      and ≤ 44 mm in length (by visual estimate) in native coronary arteries ≥2.5 mm to ≤4.0 mm in&#xD;
      diameter (by visual estimate).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2018</start_date>
  <completion_date type="Actual">January 8, 2021</completion_date>
  <primary_completion_date type="Actual">January 16, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, open label, single arm, multi-center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure Rate at 12-months</measure>
    <time_frame>12-month</time_frame>
    <description>The primary endpoint is the 12-month Target Lesion Failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR) Rate at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>The TLR overall rate includes: TLR Percutaneous Coronary Intervention (PCI) and TLR Coronary Artery Bypass Graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR) Rate at 12 Months.</measure>
    <time_frame>12 months</time_frame>
    <description>TVR overall includes: TVR PCI and TVR CABG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF) Rate at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Target Vessel Failure is defined as any ischemic-driven revascularization of the target vessel, MI related to the target vessel, or any cardiac death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI (Q-wave and Non-Q-wave) Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The MI rate includes: MIs related to the Target Vessel, MIs with unknown relationship to the Target Vessel and MIs not related to the Target Vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac death is defined as death due to any of the following; acute MI, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, CVA through hospital discharge or CVA suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery and any death in which a cardiac cause cannot be excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac Death Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Non-cardiac death is defined as a death not due to cardiac causes as previously defined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or MI Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death or MI Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/MI/TVR Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural Technical Success Rate</measure>
    <time_frame>Day 1 (periprocedural)</time_frame>
    <description>Successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization, and post-procedure diameter stenosis of &lt;30% in 2 near-orthogonal projections with Thrombolysis in Myocardial Infarction (TIMI) 3 flow in the target lesion, as visually assessed by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural Clinical Procedural Success Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Post-procedure lesion diameter stenosis &lt;30% in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician, without the occurrence of in-hospital cardiac death, MI, or TVR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>SYNERGY 48 mm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYNERGY 48 mm</intervention_name>
    <description>A drug eluting coronary stent system</description>
    <arm_group_label>SYNERGY 48 mm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Clinical Inclusion Criteria&#xD;
&#xD;
          -  Subject must be at least 18 years of age&#xD;
&#xD;
          -  Subject (or legal guardian) understands the trial requirements and the treatment&#xD;
             procedures and provides written informed consent before any trial-specific tests or&#xD;
             procedures are performed&#xD;
&#xD;
          -  Subject is eligible for percutaneous coronary intervention (PCI) and is an acceptable&#xD;
             candidate for coronary artery bypass grafting (CABG)&#xD;
&#xD;
          -  Subject has either:&#xD;
&#xD;
               -  Symptomatic coronary artery disease with one of the following: stenosis ≥ 70%,&#xD;
                  abnormal fractional flow reserve (FFR), abnormal stress or imaging stress test,&#xD;
                  or elevated biomarkers prior to the procedure&#xD;
&#xD;
               -  OR&#xD;
&#xD;
               -  Documented silent ischemia based on one of the following: abnormal fractional&#xD;
                  flow reserve (FFR), abnormal stress or imaging stress test, or elevated&#xD;
                  biomarkers prior to the procedure&#xD;
&#xD;
          -  Subject is willing to comply with all protocol-required follow-up evaluation&#xD;
             Angiographic Inclusion Criteria (visual estimate)&#xD;
&#xD;
          -  Target lesion must be located in a native coronary artery with a visually estimated&#xD;
             reference vessel diameter (RVD) ≥2.5 mm and ≤4.0 mm&#xD;
&#xD;
          -  Target lesion length must be &gt;34 mm and ≤44 mm (by visual estimate)&#xD;
&#xD;
          -  Target lesion must have visually estimated stenosis ≥50% and &lt;100% with thrombolysis&#xD;
             in Myocardial Infarction (TIMI) flow &gt;1&#xD;
&#xD;
          -  Coronary anatomy is likely to allow delivery of a study device to the target lesion&#xD;
&#xD;
          -  The target lesion must be successfully predilated/pretreated. If a non-target lesion&#xD;
             is treated, it should be treated first and should be deemed an angiographic success&#xD;
             Note: Angiographic success is a mean lesion diameter stenosis &lt; 50% (&lt; 30% for stents)&#xD;
             in 2 near-orthogonal projections with TIMI 3 flow, as visually assessed by the&#xD;
             physician, without the occurrence of prolonged chest pain or ECG changes consistent&#xD;
             with MI.&#xD;
&#xD;
        Note: Successful predilatation/pretreatment refers to dilatation with a balloon catheter of&#xD;
        appropriate length and diameter, or pretreatment with directional or rotational coronary&#xD;
        atherectomy, laser or cutting/scoring balloon with no greater than 50% residual stenosis&#xD;
        and no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C.&#xD;
&#xD;
        Clinical Exclusion Criteria&#xD;
&#xD;
          -  Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with&#xD;
             acute ST elevation MI (STEMI)&#xD;
&#xD;
          -  Subject has cardiogenic shock, hemodynamic instability requiring inotropic or&#xD;
             mechanical circulatory support, intractable ventricular arrhythmias, or ongoing&#xD;
             intractable angina&#xD;
&#xD;
          -  Subject has received an organ transplant or is on a waiting list for an organ&#xD;
             transplant&#xD;
&#xD;
          -  Subject is receiving or scheduled to receive chemotherapy within 30 days before or&#xD;
             after the index procedure&#xD;
&#xD;
          -  Planned PCI (including staged procedures) or CABG after the index procedure&#xD;
&#xD;
          -  Subject previously treated at any time with intravascular brachytherapy&#xD;
&#xD;
          -  Subject has a known allergy to contrast (that cannot be adequately premedicated)&#xD;
             and/or the trial stent system or protocol-required concomitant medications (e.g.,&#xD;
             platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related&#xD;
             compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin)&#xD;
&#xD;
          -  Subject has one of the following (as assessed prior to enrollment):&#xD;
&#xD;
               -  Other serious medical illness (e.g., cancer, congestive heart failure) with&#xD;
                  estimated life expectancy of less than 24 months&#xD;
&#xD;
               -  Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)&#xD;
&#xD;
               -  Planned procedure that may cause non-compliance with the protocol or confound&#xD;
                  data interpretation&#xD;
&#xD;
          -  Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin,&#xD;
             coumadin) for indications other than acute coronary syndrome&#xD;
&#xD;
          -  Subject has a platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3&#xD;
&#xD;
          -  Subject has a white blood cell (WBC) count &lt; 3,000 cells/mm3&#xD;
&#xD;
          -  Subject has documented or suspected liver disease, including laboratory evidence of&#xD;
             hepatitis&#xD;
&#xD;
          -  Subject is on dialysis or has baseline serum creatinine level &gt;2.0 mg/dL (177µmol/L)&#xD;
&#xD;
          -  Subject has a history of bleeding diathesis or coagulopathy or will refuse blood&#xD;
             transfusions&#xD;
&#xD;
          -  Subject has had a history of cerebrovascular accident (CVA) or transient ischemic&#xD;
             attack (TIA) within the past 6 months&#xD;
&#xD;
          -  Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding&#xD;
&#xD;
          -  Subject has signs or symptoms of active heart failure (i.e., New York Heart&#xD;
             Association (NYHA) class IV) at the time of the index procedure&#xD;
&#xD;
          -  Subject is participating in another investigational drug or device clinical trial that&#xD;
             has not reached its primary endpoint&#xD;
&#xD;
          -  Subject intends to participate in another investigational drug or device clinical&#xD;
             trial within 12 months after the index procedure&#xD;
&#xD;
          -  Subject with known intention to procreate within 12 months after the index procedure&#xD;
             (women of child-bearing potential who are sexually active must agree to use a reliable&#xD;
             method of contraception from the time of screening through 12 months after the index&#xD;
             procedure)&#xD;
&#xD;
          -  Subject is a woman who is pregnant or nursing Angiographic Exclusion Criteria (visual&#xD;
             estimate)&#xD;
&#xD;
          -  Subject has more than 1 target lesion, or more than 1 target lesion and 1 non-target&#xD;
             lesion, which will be treated during the index procedure Note: Multiple focal stenoses&#xD;
             will be considered as a single lesion if they can be completely covered with 1 study&#xD;
             stent&#xD;
&#xD;
          -  Treatment of lesions in more than 2 major epicardial vessels Note: 1 target lesion in&#xD;
             the target vessel and 1 non-target lesion in non-target vessel is allowed&#xD;
&#xD;
          -  Subject has unprotected left main coronary artery disease (&gt;50% diameter stenosis)&#xD;
&#xD;
          -  Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent,&#xD;
             cutting balloon atherectomy) within 24 hours prior to the index procedure&#xD;
&#xD;
          -  Thrombus, or possible thrombus, present in the target vessel (by visual estimate)&#xD;
&#xD;
          -  Target lesion meets any of the following criteria:&#xD;
&#xD;
          -  Treatment of a single lesion with more than 1 stent&#xD;
&#xD;
          -  Left main location&#xD;
&#xD;
          -  Lesion is located within 3 mm of the origin of the left anterior descending (LAD)&#xD;
             coronary artery or left circumflex (LCx) coronary artery by visual estimate&#xD;
&#xD;
          -  Lesion is located within a saphenous vein graft or an arterial graft&#xD;
&#xD;
          -  Lesion will be accessed via a saphenous vein graft or arterial graft&#xD;
&#xD;
          -  Lesion with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire&#xD;
             crossing&#xD;
&#xD;
          -  Lesion treated during the index procedure that involves a complex bifurcation (e.g.,&#xD;
             bifurcation lesion requiring treatment with more than 1 stent)&#xD;
&#xD;
          -  Lesion is restenotic from a previous stent implantation or study stent would overlap&#xD;
             with a previous stent&#xD;
&#xD;
          -  Non-target lesion meets any of the following criteria:&#xD;
&#xD;
          -  Located within the target vessel&#xD;
&#xD;
          -  Left main location&#xD;
&#xD;
          -  Lesion is located within a saphenous vein graft or an arterial graft&#xD;
&#xD;
          -  Lesion with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire&#xD;
             crossing&#xD;
&#xD;
          -  Lesion treated during the index procedure that involves a complex bifurcation (e.g.,&#xD;
             bifurcation lesion requiring treatment with more than 1 stent)&#xD;
&#xD;
          -  Requires additional unplanned stents (treatment of the non-target lesion with more&#xD;
             than one stent is permitted as long as the stents are initially planned)&#xD;
&#xD;
          -  Treatment not deemed an angiographic success Note: Angiographic success is a mean&#xD;
             lesion diameter stenosis &lt; 50% (&lt; 30% for stents) in 2 near-orthogonal projections&#xD;
             with TIMI 3 flow, as visually assessed by the physician, without the occurrence of&#xD;
             prolonged chest pain or ECG changes consistent with MI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitrios Karmpaliotis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast St. Joseph's Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Center for Research and Education at Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart &amp; Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P. Stradins University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Latvia</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <results_first_submitted>January 15, 2021</results_first_submitted>
  <results_first_submitted_qc>January 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2021</results_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-Eluting Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03350542/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 100 patients have been enrolled in the study from April 12, 2018 until January 17, 2019. The Evolve 48 study is anticipated to be completed (final 2-year follow up) in 2021.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SYNERGY 48 mm</title>
          <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 12-Month Clinical F/U</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Death With no 12-month F/U</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SYNERGY 48mm</title>
          <description>SYNERGY is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.99" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, of African heritage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not disclosed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Smoking, ever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking, current</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking, previous</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medically Treated Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyperlipidemia requiring medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension requiring medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of bleeding disorder</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Transient Ischemic Attack (TIA) or Coronary vasospasm (CVA)</title>
          <population>For baseline categorical variables, &quot;unknown&quot; responses and missing values will not be counted in rate denominators</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of TIA</title>
          <population>For baseline categorical variables, &quot;unknown&quot; responses and missing values will not be counted in rate denominators</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of CVA</title>
          <population>For baseline categorical variables, &quot;unknown&quot; responses and missing values will not be counted in rate denominators</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of renal disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Peripheral Vascular Disease (PVD)</title>
          <population>For baseline categorical variables, &quot;unknown&quot; responses and missing values will not be counted in rate denominators</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline lesion characteristics as determined by the Angiographic core lab, ITT analysis set</title>
          <description>Intent-to-Treat (ITT)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Left Anterior Descending (LAD)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Circumflex Artery (LCx)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Coronary Artery (RCA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Main Coronary Artery (LMCA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Target Lesion Failure Rate at 12-months</title>
        <description>The primary endpoint is the 12-month Target Lesion Failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.</description>
        <time_frame>12-month</time_frame>
        <population>The per-protocol and ITT populations are the same.</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure Rate at 12-months</title>
          <description>The primary endpoint is the 12-month Target Lesion Failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.</description>
          <population>The per-protocol and ITT populations are the same.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR) Rate at 12 Months</title>
        <description>The TLR overall rate includes: TLR Percutaneous Coronary Intervention (PCI) and TLR Coronary Artery Bypass Graft (CABG)</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat population</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR) Rate at 12 Months</title>
          <description>The TLR overall rate includes: TLR Percutaneous Coronary Intervention (PCI) and TLR Coronary Artery Bypass Graft (CABG)</description>
          <population>Intent-to-Treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR) Rate at 12 Months.</title>
        <description>TVR overall includes: TVR PCI and TVR CABG</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR) Rate at 12 Months.</title>
          <description>TVR overall includes: TVR PCI and TVR CABG</description>
          <population>Intent-to-Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF) Rate at 12 Months</title>
        <description>Target Vessel Failure is defined as any ischemic-driven revascularization of the target vessel, MI related to the target vessel, or any cardiac death.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF) Rate at 12 Months</title>
          <description>Target Vessel Failure is defined as any ischemic-driven revascularization of the target vessel, MI related to the target vessel, or any cardiac death.</description>
          <population>Intent-to-Treat analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MI (Q-wave and Non-Q-wave) Rate</title>
        <description>The MI rate includes: MIs related to the Target Vessel, MIs with unknown relationship to the Target Vessel and MIs not related to the Target Vessel.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>MI (Q-wave and Non-Q-wave) Rate</title>
          <description>The MI rate includes: MIs related to the Target Vessel, MIs with unknown relationship to the Target Vessel and MIs not related to the Target Vessel.</description>
          <population>Intent-to-Treat analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death Rate</title>
        <description>Cardiac death is defined as death due to any of the following; acute MI, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, CVA through hospital discharge or CVA suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery and any death in which a cardiac cause cannot be excluded.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death Rate</title>
          <description>Cardiac death is defined as death due to any of the following; acute MI, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, CVA through hospital discharge or CVA suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery and any death in which a cardiac cause cannot be excluded.</description>
          <population>Intent-to-Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-cardiac Death Rate</title>
        <description>Non-cardiac death is defined as a death not due to cardiac causes as previously defined.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Non-cardiac Death Rate</title>
          <description>Non-cardiac death is defined as a death not due to cardiac causes as previously defined.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death Rate</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>All Death Rate</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or MI Rate</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or MI Rate</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death or MI Rate</title>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>All Death or MI Rate</title>
          <population>Intent-to-Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/MI/TVR Rate</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/MI/TVR Rate</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis Rate</title>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis Rate</title>
          <population>Intent-to-Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Periprocedural Technical Success Rate</title>
        <description>Successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization, and post-procedure diameter stenosis of &lt;30% in 2 near-orthogonal projections with Thrombolysis in Myocardial Infarction (TIMI) 3 flow in the target lesion, as visually assessed by the physician.</description>
        <time_frame>Day 1 (periprocedural)</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Periprocedural Technical Success Rate</title>
          <description>Successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization, and post-procedure diameter stenosis of &lt;30% in 2 near-orthogonal projections with Thrombolysis in Myocardial Infarction (TIMI) 3 flow in the target lesion, as visually assessed by the physician.</description>
          <population>Intent-to-Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Periprocedural Clinical Procedural Success Rate</title>
        <description>Post-procedure lesion diameter stenosis &lt;30% in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician, without the occurrence of in-hospital cardiac death, MI, or TVR.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>SYNERGY 48 mm</title>
            <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Periprocedural Clinical Procedural Success Rate</title>
          <description>Post-procedure lesion diameter stenosis &lt;30% in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician, without the occurrence of in-hospital cardiac death, MI, or TVR.</description>
          <population>Intent-to-Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Site-Reported Serious Adverse Events (SAE) to 12 Months</time_frame>
      <desc>For All Cause Mortality, the at risk population (denominator) is the ITT population.&#xD;
For the SAE/AE tables, the at risk population (denominator) is the ITT population.</desc>
      <group_list>
        <group group_id="E1">
          <title>SYNERGY 48 mm</title>
          <description>SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)&#xD;
SYNERGY 48 mm: A drug eluting coronary stent system</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Chronic left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Plaque shift</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Patricia O'Mara</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>518-744-0046</phone>
      <email>patricia.omara@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

